Curative Biotechnology Stock Total Debt
| CUBT Stock | USD 0.01 0 8.70% |
Curative Biotechnology fundamentals help investors to digest information that contributes to Curative Biotechnology's financial success or failures. It also enables traders to predict the movement of Curative Stock. The fundamental analysis module provides a way to measure Curative Biotechnology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Curative Biotechnology stock.
Curative |
Curative Biotechnology Company Total Debt Analysis
Curative Biotechnology's Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Curative Biotechnology Total Debt | 2.26 M |
Most of Curative Biotechnology's fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Curative Biotechnology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Based on the latest financial disclosure, Curative Biotechnology has a Total Debt of 2.26 M. This is 99.92% lower than that of the Biotechnology sector and 99.3% lower than that of the Health Care industry. The total debt for all United States stocks is 99.96% higher than that of the company.
Curative Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Curative Biotechnology's direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Curative Biotechnology could also be used in its relative valuation, which is a method of valuing Curative Biotechnology by comparing valuation metrics of similar companies.Curative Biotechnology is currently under evaluation in total debt category among its peers.
Curative Fundamentals
| Return On Equity | -3.98 | |||
| Return On Asset | -0.52 | |||
| Current Valuation | 12.56 M | |||
| Shares Outstanding | 903.26 M | |||
| Shares Owned By Insiders | 0.05 % | |||
| Price To Sales | 158.53 X | |||
| Revenue | 132.32 K | |||
| Gross Profit | 100.21 K | |||
| EBITDA | (2.5 M) | |||
| Net Income | (3.96 M) | |||
| Cash And Equivalents | 126.85 K | |||
| Total Debt | 2.26 M | |||
| Debt To Equity | 6.60 % | |||
| Current Ratio | 0.10 X | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (486.58 K) | |||
| Earnings Per Share | (0.01) X | |||
| Beta | 214.95 | |||
| Market Capitalization | 11.29 M | |||
| Total Asset | 2.6 M | |||
| Retained Earnings | (38.23 M) | |||
| Working Capital | (4.42 M) | |||
| Net Asset | 2.6 M |
About Curative Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Curative Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Curative Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Curative Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Curative Stock Analysis
When running Curative Biotechnology's price analysis, check to measure Curative Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Curative Biotechnology is operating at the current time. Most of Curative Biotechnology's value examination focuses on studying past and present price action to predict the probability of Curative Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Curative Biotechnology's price. Additionally, you may evaluate how the addition of Curative Biotechnology to your portfolios can decrease your overall portfolio volatility.